SMARCB1 and neoplasm: To find these tumor-driving regulatory changes, we lentivirally transduced an MRT PDO model (named P103)23 with either a Luciferase expression (Control) or a SMARCB1 expression (SMARCB1 + ) plasmid and measured chromatin accessibility by assay for transposase-accessible chromatin using sequencing (ATAC-seq) and BAF chromatin occupancy by chromatin immunoprecipitation sequencing (ChIP-seq) or Cleavage Under Targets & Release Using Nuclease sequencing (CUT&RUN) (Fig. 1A, B and Supplementary Fig. 2A, Supplementary Data 1).